FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series B / Biotech startups that raised Series B in Asia

Biotech startups that raised Series B in Asia

Updated 16 Nov 2026

Reset
Biotech startups that raised Series B in Asia
One-time CSV
  • 457 funded companies, 334 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-b~asia.csv457 rows × 18 columns
CompanyCityLast roundAmountDate
Huasaiboman Medical Cell BiologyQingdao ShiSeries B$30.0M2026-11-09
EnjosimShanghaiSeries B$30.1M2026-11-02
Celaid TherapeuticsTokyoSeries B$2.5M2026-10-05
HITSSeoulSeries B$13.5M2026-09-28
Bluesail SurgicalShanghaiSeries B$104.5M2026-09-23
MedefaZhuhaiSeries B$14.9M2026-09-02
Yuce BiotechnologySuzhouSeries B$7.4M2026-08-31
Hongxin BiologyShenzhenSeries B$14.0M2026-08-13

8 rows of the CSV in 5 of its 18 columns.

457
Startups
$11.1B
Total raised
68
Funded in the last 12 months
$1.4B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 457
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi, China Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai, China Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
Celaid Therapeutics Celaid Therapeutics develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders. Biotech Tokyo, Japan Series B $2.5M 2026-10-05 $17.1M UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Joyo Capital Partners 1 to 10 2020
HITS HITS develops artificial intelligence software for drug discovery and pharmaceutical research. Artificial intelligence Seoul, South Korea Series B $13.5M 2026-09-28 $25.1M Korea Investment Partners, Capstone Partners, Company K Partners +2 11 to 50 2020
Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai, China Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
Medefa Medefa uses synthetic biology to mass-produce novel PHA biomaterials. Biotech Zhuhai, China Series B $14.9M 2026-09-02 $16.3M Motianshi Touzi, Taiping Innovation 11 to 50 2019
Yuce Biotechnology Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. Biotech Suzhou, China Series B $7.4M 2026-08-31 $22.4M Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 101 to 250 2019
Hongxin Biology Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. Biotech Shenzhen, China Series B $14.0M 2026-08-13 $14.0M Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group 11 to 50 2021
Layerwave Bio Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. Biotech Daxing, China Series B $13.8M 2026-07-28 $13.8M IDG Capital, Addor Capital, Hotung Venture Capital 51 to 100 2020
MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai, China Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
ThunderBio Innovation ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. Biotech Jiaxing, China Series B $17.7M 2026-06-15 $34.6M Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi 11 to 50 2018
HemaCell HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. Biotech Suzhou, China Series B $14.8M 2026-06-02 $62.0M Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation 1 to 10 2021
Phytolon Phytolon supplies natural food colors of high quality at low cost. Biotech Yoqne`am `illit, Israel Series B $23.6M 2026-05-26 $43.7M MassChallenge, Trendlines Group, Millenium Food-Tech 11 to 50 2018
Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai, China Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
Novamab Novamab researches and develops new nanobodies. Biotech Shanghai, China Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
Restore Vision Restore Vision develops a gene therapy to restore vision for patients with retinitis pigmentosa. Biotech Tokyo, Japan Series B $8.2M 2026-04-15 $26.7M SMBC Venture Capital, ANRI, Spiral Capital +2 1 to 10 2016
AnBogen Therapeutics Anbogen Therapeutics is a clinical-stage biotech company developing science to help cancer patients. Biotech Nankang, Taiwan Series B $7.3M 2026-04-13 $19.8M National Development Fund of Taiwan Government, China Development Industrial Bank (CDIB), Maxpro Ventures +1 11 to 50 2019
CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian, China Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
Findcure Findcure develops anti-cancer medications through drug discovery and development. Biotech Daxing, China Series B $14.5M 2026-02-14 $14.5M Hecheng Capital, Renxi Fund, Yishang Huicheng Investments 11 to 50 2019
Transcend Vivoscope Transcend Vivoscope is a biotechnology company that offers advanced microscopy imaging products and solutions. Biotech Haidian, China Series B $14.5M 2026-02-10 $14.5M China Capital Management, Zefu Innovation, Guangzhou Tongxin Science and Technology Innovation Fund 11 to 50 2016
Galux Galux designs molecules to discover new drugs for incurable and rare diseases. Artificial intelligence Dogokdong, South Korea Series B $29.0M 2026-02-09 $36.3M Dayli Partners 11 to 50 2020
Pandorum Technologies Pandorum Technologies is a Bengaluru-based biotech startup. Biotech Bangalore, India Series B $18.0M 2026-02-09 $42.6M 500 Global, IAN Group, 021 Capital +1 11 to 50 2011
Alioth Alioth develops and applies technical products for pharmaceutical process technology. Biotech Shanghai, China Series B $14.4M 2026-01-15 $54.7M Matrix Partners China, Legend Capital 51 to 100 2021
Anlong Bio Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. Biotech Beijing, China Series B $14.3M 2026-01-07 $14.3M TaiKun Fund 51 to 100 2019
D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi, China Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
Rigen Biotech Rigen Biotech provides molecular diagnosis of thyroid tumors. Biotech Minhang, China Series B $14.1M 2025-11-28 $29.8M BioTrack Capital, Boyuan Capital, Guotai Junan Innovation Investment +1 101 to 250 2017
CytoReason CytoReason develops a cell-centered computational model of the human body to find patterns in biological data. Artificial intelligence Tel Aviv, Israel Series B $80.0M 2024-07-17 $100.0M OurCrowd, Asymmetry Ventures, Pfizer 101 to 250 2016
LN Robotics LN Robotics is a technology research firm that develops medical robots. Biotech Hanam, South Korea Series B $14.5M 2024-07-09 $21.3M TIPS Program, Bluepoint, Mirae Asset Venture Investment +2 11 to 50 2019
Alpha Biopharma Alpha Biopharma is a clinical-stage biopharmaceutical company. Biotech Huangpu, China Series B $23.9M 2024-06-22 Qiming Venture Partners, TF Capital, LYZZ Capital 51 to 100 2017
DOT Compliance DOT Compliance provides a ready-to-use cloud-based quality and compliance management solution for regulated industries. Biotech Ness Ziona, Israel Series B $17.5M 2024-04-15 Vertex Ventures, TPY Capital, Israel Growth Partners 101 to 250 2007

Table 1. Biotech startups that raised Series B in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 457.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi, China Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
2 Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai, China Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
3 Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai, China Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
4 MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai, China Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
5 CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian, China Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
6 Novamab Novamab researches and develops new nanobodies. Biotech Shanghai, China Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
7 Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai, China Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
8 Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi, China Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
9 Galux Galux designs molecules to discover new drugs for incurable and rare diseases. Artificial intelligence Dogokdong, South Korea Series B $29.0M 2026-02-09 $36.3M Dayli Partners 11 to 50 2020
10 Phytolon Phytolon supplies natural food colors of high quality at low cost. Biotech Yoqne`am `illit, Israel Series B $23.6M 2026-05-26 $43.7M MassChallenge, Trendlines Group, Millenium Food-Tech 11 to 50 2018

Table 2. Biotech startups that raised Series B in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 7 2% 2 Novamab, CSR Biotech
2 CMB International Capital Corporation Investment bank Central, Hong Kong 5 1% 1 HemaCell
3 Matrix Partners China Venture capital firm Beijing, China 5 1% 2 Alioth, D3 Bio
4 BioTrack Capital Venture capital firm Shanghai, China 4 1% 2 Yuce Biotechnology, Rigen Biotech
5 Northern Light Venture Capital Venture capital firm Beijing, China 4 1% 1 HemaCell
6 Legend Capital Venture capital firm Beijing, China 4 1% 1 Alioth
7 UTEC - The University of Tokyo Edge Capital Partners Venture capital firm Tokyo, Japan 3 1% 1 Celaid Therapeutics
8 Huagai Capital Private equity firm Beijing, China 3 1% 2 Bluesail Surgical, MindRank AI
9 Addor Capital Venture capital firm Nanjing, China 3 1% 1 Layerwave Bio
10 IDG Capital Private equity firm Beijing, China 3 1% 1 Layerwave Bio
11 GL Ventures LLC Venture capital firm Beijing, China 3 1% 1 Etern
12 Gaorong Capital Venture capital firm Wangjing, China 3 1% 1 Bivision
13 Lilly Asia Ventures Venture capital firm Shanghai, China 3 1%
14 CICC Capital Private equity firm Beijing, China 3 1%
15 Hillhouse Ventures Venture capital firm Singapore 3 1%

Table 3. Biotech startups that raised Series B in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 395 86% $9.8B
Software 32 7% $837.5M
Artificial intelligence 20 4% $731.6M
Hardware 17 4% $120.2M
Education 3 1% $18.7M
Fintech 2 0%
Energy 2 0% $816.8M
Cybersecurity 2 0%

Table 4. Biotech startups that raised Series B in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 457 100% $14.5M

Table 5. Biotech startups that raised Series B in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
China 301 66%
South Korea 75 16%
Israel 26 6%
Japan 23 5%
Singapore 10 2%
India 9 2%
Taiwan 7 2%
Hong Kong 6 1%

Table 6. Biotech startups that raised Series B in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 53 12%
Beijing 31 7%
Suzhou 28 6%
Seoul 25 5%
Hangzhou 23 5%
Shenzhen 18 4%
Guangzhou 11 2%
Nanjing 11 2%
Seongnam 11 2%
Tokyo 10 2%
Singapore 10 2%
Changping 8 2%

Table 7. Biotech startups that raised Series B in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 4 6% $75.0M
October 2026 3 4% $13.9M
September 2026 9 13% $257.3M
August 2026 2 3% $21.5M
July 2026 4 6% $65.8M
June 2026 5 7% $79.3M
May 2026 5 7% $138.4M
April 2026 6 9% $91.0M
March 2026 4 6% $230.9M
February 2026 7 10% $133.7M
January 2026 9 13% $98.0M
December 2025 8 12% $226.0M
November 2025 2 3% $14.1M

Table 8. Biotech startups that raised Series B in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 58 13% $1.2B
2025 51 11% $839.3M
2024 38 8% $483.2M
2023 61 13% $981.3M
2022 71 16% $2.6B
2021 55 12% $2.4B

Table 9. Biotech startups that raised Series B in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 0%
2020 to 2022 69 15%
2015 to 2019 221 48%
2010 to 2014 92 20%
Before 2010 73 16%

Table 10. Biotech startups that raised Series B in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 43 10%
11 to 50 171 41%
51 to 100 91 22%
101 to 250 71 17%
251 to 500 22 5%
501 to 1,000 14 3%
1,001 to 5,000 8 2%

Table 11. Biotech startups that raised Series B in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Asia whose last round is Series B are on the list?
457, in the file dated 16 November 2026. 68 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 457 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series B in Asia: 457 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Asia

Other sectors that raised Series B in Asia

Cite: FundingWatcher, 457 biotech companies in Asia whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-b/asia/